Clinical Trial

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapiesNEW HAVEN,…

8 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90).The Company to…

8 months ago

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

8 months ago

Bioma Review 2025: Weight Loss Probiotic or Just Another Scam? – Ingredients & Side Effects Revealed !! By Bioma

Bioma Bioma Birštonas Lithuania, April 20, 2025 (GLOBE NEWSWIRE) -- Are you looking for a reliable solution to improve your…

8 months ago

GenF20 Plus Under Review: Why Choose GenF20 Plus Over The Other Popular HGH Releaser Supplement?

GenF20 Plus® is an all-natural supplement that is clinically-proven to reverse the signs of aging by boosting your Human Growth…

8 months ago

New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT),…

8 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…

8 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company")…

8 months ago